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DObjective: The present study assessed the clinical and echocardiographic outcomes for 1000 patients undergo-
ing minimally invasive mitral valve surgery.
Methods: The Brigham Cardiac Valve database was reviewed. From August 1996 to November 2011, 1000
patients had undergone minimally invasive mitral valve surgery (median follow-up, 7 years). Data on the sur-
gical approach, complications, reoperations, and late survival were tabulated. Late echocardiographic data on
the recurrence of mitral regurgitation after mitral repair in myxomatous disease were also collected. Survival,
freedom from reoperation and recurrent mitral regurgitation (grade  3þ) were evaluated with life tables
and Kaplan-Meier analyses.
Results: Themean patient agewas 57 years. Of the 1000 patients, 41%werewomen.Myxomatous degenerative
disease was the predominant pathologic entity (86%). A lower hemisternotomy was the predominant surgical
approach (75%). Mitral repair was performed in 923 patients and replacement in 77. Eight operative deaths
(0.8%) occurred. A total of 44 patients with failed mitral repairs underwent reoperation, with 1 mitral valve re-
placed again on the same operative day for atrioventricular groove disruption. Nine failed repairs were repaired
again (9/44 [20%]). A total of 106 late deaths occurred. The overall survival at 15 years was 79%  3%. Free-
dom from reoperation at 15 years was 90% 3% for repairs and 100% for replacements. Late echocardiograms
were acquired for 615 of 815 eligible mitral repair patients with myxomatous disease (75%). Freedom from re-
current mitral regurgitation (grade  3þ) at 1, 5, and 10 years was 99%  1%, 87%  2%, and 69%  4%,
respectively.
Conclusions:Minimally invasive mitral valve surgery is effective, with excellent late results. The durability of
minimally invasive mitral valve repair compared favorably with conventional full sternotomy methods at late
follow-up. (J Thorac Cardiovasc Surg 2013;145:1199-206)Minimally invasive mitral valve surgery (mini-MVS) has
been in use for 15 years.1,2 Built on the premise that less
invasive surgery could expedite postoperative recovery
owing to a reduction in surgical trauma with limited
access techniques, resulting in reduced hospital stays,
reduced hospital costs, improved cosmesis, and increased
patient satisfaction, mini-MVS continues to be steadily
adopted, with more and more advocates over time.3 At its
inception, mini-MVS focused solely on smaller incisions,
specifically the parasternal incision, and upper and lower
hemisternotomy. Although the parasternal approach has
fallen out of favor, the upper and lower hemisternotomye Division of Cardiac Surgery, Brigham and Women’s Hospital, Harvard
cal School, Boston, Mass.
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The Journal of Thoracic and Carcontinue to be used by many, along with the now predomi-
nant approach at most centers, the small right anterior tho-
racotomy. In conjunction with these techniques, robotics
and thoracoscopic instruments have gradually been intro-
duced as adjuncts to further minimize the surgical trauma
and have been championed at select cardiac centers.4,5 A
multitude of studies have supported the safety of mini-
MVS in the immediate postoperative period, and a few
select case series have shown excellent midterm outcomes
with these techniques.1-9 However, data to assess the
long-term outcomes with mini-MVS remain relatively
sparse. Although establishing the safety of mini-MVS is
pertinent, the true testament to its continued assimilation
will be twofold: (1) to ensure that limited exposure with
mini-MVS is not a direct cause for mitral valve replacement
instead of mitral valve repair in patients for whom repair
would clearly be the preferred therapy; and (2) to ensure
the long-term mitral valve durability is on par with that
achieved using conventional full sternotomy methods. If
the perceived early benefits of mini-MVS are achieved at
the expense of a greater propensity to replace complex
regurgitant valves that would otherwise have been repaired,
or at the expense of a greater reoperation rate secondary to
subpar repair durability, the minimally invasive techniquesdiovascular Surgery c Volume 145, Number 5 1199
Abbreviations and Acronyms
mini-MVS ¼ minimally invasive mitral valve
surgery
MR ¼ mitral regurgitation
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Dwill be counterproductive and arguably unwarranted. In an
effort to critically appraise the long-term clinical and echo-
cardiographic results with mini-MVS, we report on a con-
secutive series of 1000 patients who had undergone mitral
valve surgery using minimally invasive techniques at the
Brigham and Women’s Hospital during a 15-year period.METHODS
The present study was a retrospective, observational review of all
patients who underwent a minimally invasive mitral valve procedure
from July 1, 1996 to November 30, 2011. The institutional review board
approved the study and waived patient consent.
The patient demographics, medical history, and operative and in-
hospital outcomes were collected at each patient’s admission and at each
consecutive follow-up visit. The data were coded according to the defined
definitions of the Society of Thoracic Surgeons Adult Cardiac Database,
version 2.52. Long-term mortality was documented through to December
31, 2011, with a review of the data collected from routine clinic follow-
up visits, in addition to a query of the Social Security Death Index. Data
on late reoperations or reintervention were similarly sought through routine
clinic follow-up visits, periodic patient questionnaires, and contact with the
primary care practitioners or referring cardiologists. The main outcomes of
interest were early and late mortality, mitral valve-related reoperations, and
the recurrence of moderate (grade 3þ) or severe (grade 4þ) mitral regur-
gitation (MR). The postoperative in-hospital morbidity data for stroke,
reoperation for bleeding, permanent pacemaker insertion, deep sternal
wound infection, new-onset atrial fibrillation, renal failure, and packed
red blood cell transfusions were also assessed.
Late follow-up echocardiograms (defined as 6 months) were sought
for all eligible patients with myxomatous degenerative disease who had
undergone minimally invasive mitral valve repair. Late echocardiograms
absent from the Brigham Cardiac Valve database were obtained from the
primary care practitioners or referring cardiologists, when available.
When assessing late MR recurrence, the echocardiogram on file that was
farthest from the initial surgery or, in the case of reoperation, the echocar-
diogram immediately before that reoperation, was used. RecurrentMRwas
defined as moderate or severe on a 4-point scale (1þ [trace], 2þ [mild], 3þ
[moderate], and 4þ [severe]). The exclusion criteria for recurrentMR anal-
ysis were patients who had undergone mitral valve replacement, patients
who had undergone mitral valve repair for a nonmxyomatous etiology, pa-
tients with less than 6 months of follow-up because of early death or early
reoperation, and patients with less than 6 months from surgery to the start
of the study. Of the 923 patients who underwent mitral repair, 108 patients
met the exclusion criteria, leaving 815 eligible patients. Of these 815
patients, a late follow-up echocardiogram was acquired in 615 (75%).
Surgical Techniques
Patient selection was predicated by surgeon preference. Absolute con-
traindications to a minimally invasive approach included surgically signif-
icant coronary artery disease, chest wall deformities, and morbid obesity.
Surgical access was predominantly through a lower hemisternotomy.
Our technique has been described previously.10 In brief, a 6-cm skin inci-
sion, 2 fingerbreadths distal to themanubrium,was extended distal to a level
2 fingerbreadths proximal to the xiphoid process. A hemisternotomy was1200 The Journal of Thoracic and Cardiovascular Surperformed from the xiphoid to the second intercostal space and extended
into the second intercostal space on the right side using an oscillating
saw. The ascending aorta was cannulated directly with percutaneous cannu-
lation of the inferior vena cava by way of the femoral vein with the assis-
tance of transesophageal echocardiography.
When using a right anterior thoracotomy, our approach was similar to
that described by others,8 with slight modifications. Access was primarily
through the fourth intercostal space by way of a 6-cm skin incision made
either just below the nipple or within the inframammary crease for men
and women, respectively. Cardiopulmonary bypass was initiated by way
of the femoral artery and vein cannulation through a small transverse inci-
sion in the groin. An 8-mm tube graft was sewn to the femoral artery and
attached to the arterial cannula, and the femoral vein was percutaneously
accessed and guided up to the inferior vena cava–right atrial junction, again
with transesophageal echocardiography guidance. Percutaneous cannula-
tion of the superior vena cava was also instituted to maximize venous drain-
age. The aorta was crossclamped using the flexible Cosgrove aortic clamp
(CareFusion V. Mueller, Waukegan, Ill) directly through the thoracotomy
incision.
For both approaches, the lower hemisternotomy and right anterior tho-
racotomy, barring factors that would necessitate access to the right atrium
(tricuspid valve pathologic features, patent foramen ovale), the mitral valve
is preferentially approached through the interatrial groove. Moreover, un-
dersize (16F-24F) vacuum-assisted cannulas are used with both techniques
to optimize exposure and maintain venous drainage. Myocardial protection
is primarily through antegrade cardioplegia for both techniques.
Statistical Analysis
All statistical analyses were performed with the assistance of a depart-
mental statistician. Fisher’s exact test was used to evaluate the dichotomous
variables. t Tests with Levine’s homogeneity of variance or the Mann-
WhitneyU test were used for continuous variables, as appropriate. Survival
and freedom from recurrence of moderate or severe (grade 3þ) MRwere
evaluated with life tables and Kaplan-Meier analyses. Categorical and di-
chotomous variables are presented as numbers and percentiles. Continuous
variables are presented as the mean standard deviation (normally distrib-
uted) or median and interquartile range (non-normal distributions). All
statistical analyses were performed using SPSS, version 13.0 (SPSS,
Chicago, Ill).
RESULTS
A total of 3133-isolated mitral valve surgeries (defined as
MVS without coronary artery bypass grafting) were per-
formed from August 1, 1996 to November 30, 2011. Mitral
valve reparative techniques were used in 2127 patients
(68%), and 1006 underwent mitral valve replacement
(32%). Of the patients from this cohort, 1000 (32%) under-
wentMVSwith a minimally invasive approach and were the
focus of the present review. Minimally invasive mitral valve
repair was the predominant treatment choice (923/1000
[92%]), with a small percentage undergoing minimally
invasive mitral valve replacement (77/1000 [8%]). The me-
dian cardiopulmonary bypass time for the complete cohort
was 118 minutes, and the median crossclamp time was 88
minutes. A single surgeon (L.H.C.) performed 77% of the
minimally invasive cases.
The patient demographics are listed in Table 1. The mean
age was 57.2  13.4 years, the mean ejection fraction was
62.5%  8%, and 408 of the patients were women (41%).
Myxomatous degenerative disease was the predominantgery c May 2013
TABLE 1. Baseline demographics (n ¼ 1000)
Variable Value
Age (y)
Mean  standard deviation 57  13
Range 17-90
Women (n) 408 (41)
NYHA functional class
Mean  standard deviation 2.0  0.7
Class III-IV (n) 244 (24)
History of cerebrovascular accident (n) 21 (2)
History of renal failure (n) 10 (1)
Reoperation (n) 12 (1)
Ejection fraction (%) 62.5  8
Mitral valve pathologic findings (n)
Mitral regurgitation 957 (96)
Mitral stenosis 10 (1)
Mitral regurgitation and mitral stenosis 33 (3)
Mitral valve disease (n)
Myxomatous 860 (86)
Rheumatic 64 (6)
Dilatative cardiomyopathy 36 (4)
Endocarditis 31 (3)
Ischemic 4 (0.4)
Mitral regurgitation grade (0-4) 3.80  0.4
Data presented as mean  standard deviation or n (%). NYHA, New York Heart
Association.
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achieved through a lower hemisternotomy in 746 cases
(75%) and a right anterior thoracotomy in 43 (4%). A para-
sternal incision was used in 204 patients (20%) early in our
minimally invasive experience, with an additional 5 patients
undergoingupper hemisternotomyand2patients left anterior
thoracotomy.
Specific to mitral valve repair, posterior leaflet resection
with amodified leaflet advancement and insertion of an annu-
loplasty ring was the predominant reparative technique.
Commissuroplasty, foldoplasty, and adjunct maneuvers
such as edge-to-edge repair or an imbrication stitch were
used, as indicated.Theuse of these techniques andother tech-
niques, and their distributive usewithin the cohort, have been
previously outlined.7 The use of these reparative techniques
has remained relatively constant since last reviewed.Early Outcomes
The postoperative mortality and morbidity were low.
In-hospital mortality was 0.8% (8 patients), with a median
length of hospital stay of 5 days. A total of 21 patients (2%)
incurred a permanent stroke, 19 patients (2%) required re-
operation for bleeding, 7 patients incurred new-onset post-
operative renal failure (0.7%), 6 patients (0.6%) required
a permanent pacemaker, and 6 patients (0.6%) developed
a deep sternal wound infection. New-onset atrial fibrillation
occurred in 201 patients (20%). Only 297 patients (30%)
were transfused at least 1 U of packed red blood cells. OfThe Journal of Thoracic and Car746 patients, 6 (1%) required conversion to full sternotomy.
Access was through a lower hemisternotomy in each case; 2
cases were for an inability to defibrillate, 3 for poor expo-
sure, and 1 for repair of an aortic dissection. Five notable,
serious complications occurred. Early in our experience, 3
patients incurred aortic dissections related to cardioplegia
needle placement. Each case was with a different surgical
approach (parasternal incision in 1, right anterior thoracot-
omy in 1, and lower hemisternotomy in 1). The lower hemi-
sternotomy was converted to full sternotomy; however, in
the parasternal and thoracotomy cases, the aortic dissec-
tions were quite focal, enabling repair through the original
surgical incision. One additional patient had a complicated
course with biventricular failure occurring when coming off
cardiopulmonary bypass, subsequent cardiogenic shock,
placement of a biventricular assist device, and eventual
heart transplantation. Finally, an elderly patient with
a heavily calcified posterior annulus underwent mitral valve
replacement and experienced an atrioventricular groove
disruption on postoperative day 1, necessitating emergent
reoperation. All 5 of these patients survived to hospital
discharge.
Mitral Valve Replacement
For the 77mitral valve replacements, rheumatic valve dis-
ease (n¼ 35, 45%) and myxomatous degeneration (n¼ 34,
44%) were the predominant pathologic entities. Endocardi-
tis in 6 patients, a double orifice congenital defect in 1, and
presumed radiation-induced valvular dysfunction in 1 pa-
tient completed the cohort. Of the 77 replacements, 6 were
planned repairs that inevitably required intraoperative
replacement (8%). Of these 6 failed intraoperative repairs,
3 were complex regurgitant valves with myxomatous Bar-
low’s type disease, 2 had excessive annular calcifications,
and 1 case had protracted leaflets in the setting of previous
radiation for lymphoma, as noted in this paragraph.
Mitral Valve Repair
Intraoperative success using minimally invasive mitral
valve repair techniques was achieved in 98% of the cases.
Of the 929 patients who underwent attempted mitral valve
repair, 6 had an intraoperative failed repair, necessitating
mitral valve replacement. For the remaining 923 patients
with successful repair at surgery, 17 required intraoperative
conversion to sternotomy (n ¼ 6) or reoperation within 6
months postoperatively (n ¼ 11). Thus, of the 929 patients,
906 (97.5%) did not require conversion or reoperation. At
late follow-up, 44mitral valve repairs had required a reoper-
ative procedure. Repeat repair was accomplished in 9
(20%), and 35 (80%) necessitated replacement.
Late Outcomes
The survival curve for the complete 1000-patient cohort
is shown in Figure 1. Follow-up for late survival wasdiovascular Surgery c Volume 145, Number 5 1201
FIGURE 1. Survival for 1000 patients who had undergone minimally invasive mitral valve surgery at late follow-up. Tabular data provide number at risk in
period ending on month noted. Estimates (mean  standard error) indicate 5-, 10-, and 15-year intervals.
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years). Survival at 5, 10, and 15 years was 93%  1%,
86% 1% and 79% 3%, respectively (median survival,
15 years; 95% confidence interval, 14.9-15.4). Freedom
from reoperation was 100% for mitral valve replacement
at late follow-up. For mitral valve repair, freedom from re-
operation at 5, 10, and 15 years was 96%  1%,
95%  1% and 90%  3%, respectively (Figure 2).
Long-term echocardiographic data were available for
815 patients who had undergone minimally invasive mitral
valve repair for myxomatous degenerative disease. Of
these, data extending 6 months or longer from surgery
were available for 615 patients (75.4%). A responder bias
analysis comparing the cohort without follow-up with the
study cohort showed the 2 groups to be substantially similar
(P  .2) in age, gender, New York Heart Association func-
tional class distribution, ejection fraction, disease etiology,
and surgical approach (data not shown).
The median interval to a postoperative echocardiographic
study was 4.6 years (range, 0.5-13.4 years), with a total of
3012 patient-years of acquired follow-up time. Freedom
from recurrent MR for the entire cohort (defined as MR
grade  3þ) at 1 year was 98.5%  0.5% (n at
risk ¼ 589), at 5 years was 87.3%  1.7% (n at
risk ¼ 257), and at 10 years was 68.8%  4.1% (n at
risk¼ 56). Because it is well established that anterior leaflet
and bileaflet pathologic features increase mitral valve repair
complexity and can have a direct effect on late MR1202 The Journal of Thoracic and Cardiovascular Surrecurrence, we assessed the durability of mitral valve repair
for anterior and bileaflet pathologic entities as a distinct
group separate frompatientswith posterior leaflet pathologic
features.11-13 The Kaplan-Meier analysis and freedom from
recurrent MR for patients with posterior leaflet repair (436/
615, 70.8%) versus anterior or bilateral leaflet repair (179/
615, 29.1%) are shown in Figure 3.Mitral valve repair dura-
bility was significantly less effective for patients with ante-
rior or bileaflet repair than for posterior leaflet repair
(P¼ .017). Freedom from recurrent MR for posterior leaflet
repair was 97% 1% at 1 year, 88% 2% at 5 years, and
76%  4% at 10 years. In contrast, the 1-, 5-, and 10-year
freedom from recurrent MR for anterior or bileaflet repair
was 96% 2%, 84% 4%, and 49% 9%, respectively.
The repair durability was similar between the 2 groups up to
the 7-yearmark, atwhich point thosewith anterior leaflet and
bileaflet pathologic features had a significantly greater pre-
cipitous increase in MR recurrence than patients with poste-
rior leaflet repairs. Event-free survival (cumulative freedom
from death, reoperation, and recurrentMR) for themyxoma-
tous cohort (815 patients) who had undergone minimally in-
vasive mitral repair is depicted in Figure 4. At 15 years,
event-free survival was 77%  4%.
DISCUSSION
Mini-MVS, aside from patient satisfaction and aes-
thetics, has long been advocated for the potential benefits
that it can provide to patients in the immediategery c May 2013
FIGURE 2. Freedom from reoperation for patients who had undergone minimally invasive mitral valve repair at late follow-up. Tabular data provide
number at risk in period ending on month noted. Estimates (mean  standard error) indicate 5-, 10-, and 15-year intervals.
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rently available evidence by Cheng and colleagues14 sug-
gested mini-MVS to be associated with decreased
bleeding, blood transfusions, atrial fibrillation, sternal
wound infections, ventilation times, stay in the intensive
care unit, and length of hospital stay and a more expeditious
return to normal activity. Moreover, these benefits result
without incurring any adverse effects in regard to valvular
reintervention or survival at follow-up extending to 8 and
9 years, respectively, in select studies.14 Although these pre-
sumed benefits are compelling and support the continued
use of minimal access techniques for mitral valve surgery,
important unanswered questions remain. The assurance
that these benefits can be achieved without influencing the
intraoperative surgical preference toward replacement
over repair and the assurance that these benefits can be
achieved without jeopardizing the long-term rates of reop-
eration or mitral valve durability are unknowns that need
additional study if mini-MVS is to continue to achieve
more widespread acceptance. Clearly, mini-MVS comes
with the adage that inherently less exposure will be avail-
able for the surgeon than that provided through a conven-
tional full sternotomy. Thus, some have challenged the
use of mini-MVS.15 It has been suggested (quite reason-
ably) that limited exposure could lead to surgical compro-
mise, with the surgeon adapting their repair techniques to
accommodate their limited space and inevitably accepting
a lower quality repair or having a lower threshold for mitralThe Journal of Thoracic and Carvalve replacement for valves that are truly repairable.15
Both are valid concerns.
Encouragingly, the present review of our initial 1000min-
imally invasive mitral valve procedures with follow-up
extending out 15 years does not substantiate either of these
points of contention. Neither the intraoperative commitment
to repair nor the long-term outcomes appeared to be nega-
tively affected by the used ofminimally invasive techniques.
The repair rate for the present series was exceedingly
high at 97.5%, with only 6 cases in which the initial attempt
at repair ultimately required replacement. We assessed
these findings more critically with a sensitivity analysis.
For this, we assumed that all 34 myxomatous mitral valves
that ultimately required mitral valve replacement could
actually have been repaired and that the field of exposure
was the deciding factor, rather than the complexity of the
myxomatous pathologic findings. Given these assumptions,
the repair rate for the entire cohort remained an impressive
94.6% (if 31 additional myxomatous valves had failed
repair, the denominator would be 929þ 29¼ 958, for a mi-
tral valve repair rate of 906/960 ¼ 94.6% vs 906/
929 ¼ 97.5%). With a mitral valve repair rate of 95% or
greater, it is difficult to conceive that the use of a minimally
invasive technique had much of an influence, if any, on the
eventual intraoperative surgical therapy used. The decision
to perform repair or replacement was more likely dictated
by the valve pathologic features and the complexity of the
disease process at intraoperative assessment.diovascular Surgery c Volume 145, Number 5 1203
FIGURE 3. Freedom from recurrent (grade 3þ) mitral regurgitation (MR) at late follow-up after minimally invasive mitral valve repair for myxomatous
degenerative disease. Patients were stratified into 2 groups: patients with posterior leaflet pathologic features and patients with anterior or bileaflet pathologic
features. Tabular data provide number at risk in period ending on month noted. Estimates (mean  standard error) indicate 1-, 5-, and 10-year intervals.
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group of patients and not every patient is suitable for
mini-MVS. It is our belief that patient selection in the pre-
operative assessment is the foremost important predictor for
success or failure with mini-MVS and that this assessment
best dictates whether successful mitral repair is foreseeable.
Very obese patients, an excessively deep thoracic cavity,
and chest wall deformities can present formidable chal-
lenges when using minimally invasive techniques. We gen-
erally recommend against the use of mini-MVS for such
patients.
In keepingwith this,which highlights the notion thatmini-
MVS does not necessarily have an influence on intraopera-
tive surgical decision-making insofar as whether to repair
or replace a particular valve, our long-term data also suggest
that the clinical outcomes and mitral valve repair durability
are not compromised by using mini-MVS techniques.
The freedom from recurrent MR (grade  3þ) for myx-
omatous disease of the posterior leaflet was 76%  4% at
10 years in our series. This was significantly better than the
49%  9% freedom from recurrent MR achieved for the
anterior/bileaflet group during the same period. Both of
these results are in line with that achieved by other groups
assessing the recurrence of late MR and mitral valve repair
durability for myxomatous disease using conventional1204 The Journal of Thoracic and Cardiovascular Surfull-sternotomy methods. Specifically David and col-
leagues,11 in a cohort of 701 patients with myxomatous
disease who underwent a full sternotomy approach, noted
a late rate of recurrent MR (grade  3þ) to be
80%  4% for posterior pathologic features, 67%  6%
for anterior pathologic features, and 65%  8% for bileaf-
let pathologic features at 12 years of follow-up. Admittedly,
direct comparisons across these observational studies could
be misleading; these were different patient populations with
differing follow-up methods. Intraobserver variability
among echocardiographers could also play a role. Also,
the diminishing return on outcome reliability as the number
of patients at risk continues to decrease with time also needs
to be considered. Still, even when factoring in such short-
comings, it is more likely that these studies are reasonably
comparable than drastically dissimilar. The Cleveland
Clinic has also published data to support the long-term du-
rability of mitral valve repair with minimally invasive tech-
niques. In a recent review of more than 3000 patients with
mitral valve repair for myxomatous disease of the posterior
leaflet, freedom from recurrence ofMRwas as great as 89%
at 10 years for the cohort, and 60% of the cases were per-
formed using minimally invasive access (upper hemister-
notomy).16 Taken together, these 3 studies suggest that
valve durability can be maintained long-term with eithergery c May 2013
FIGURE 4. Event-free survival at late follow-up in patients who underwent minimally invasive mitral valve repair for myxomatous degenerative disease.
Tabular data provide number at risk in period ending on month noted Estimates (mean  standard error) indicate 5-, 10-, and 15-year intervals.MR, Mitral
regurgitation.
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niques without jeopardizing the quality of the repair.
However, despite the potential benefits of mini-MVS and
the results of our study to suggest the long-term durability to
be maintained using these techniques, mini-MVS has
potential drawbacks that still need to be addressed. An in-
creased risk of stroke, aortic dissection, and groin complica-
tions and increased crossclamp and cardiopulmonary times
have all been mentioned as being of greater risk when per-
forming mini-MVS versus conventional techniques.3,14 In
our particular series, such complications have remained low.
Study Limitations
The present study was subject to the limitations inherent
to a single-center, retrospective, study design. The decision
to use minimally invasive surgery was surgeon specific, and
the outcomes at our center might not be generalizable to
other populations.
Althoughwe retained as many subjects as possible for our
echocardiographic analyses, echocardiographic follow-up
data were missing for 25% of eligible subjects. Although
our responder bias analysis would suggest similarities be-
tween the cohort analyzed and those who were lost to
follow-up, to the degree that these additional results would
have altered the final analysis could not be known with cer-
tainty. Because it is more likely that patients with a function-
ing mitral valve repair who remain asymptomatic would be
less likely to present for a follow-up echocardiogram versusThe Journal of Thoracic and Cartheir symptomatic counterparts, it was our assumption that
in this regard our analysis overestimated the recurrence of
significant (grade  3þ) MR, but this is purely speculative.
Furthermore, the present study might not have accurately
estimated the incidence of MR recurrence, because follow-
up echocardiographic studies are not routine. It is possible
that the follow-upwas biased toward subjectswith symptoms
of MR or a high clinical suspicion for recurrence, which
would, again, have overestimated long-termMR recurrence.
However, in contrast, by assessing the long-term recur-
rence of MR by relying on only 2 points in time (preopera-
tive echocardiographic MR vs the latest echocardiogram on
file with MR), our methods would tend to underestimate the
cohorts’ incidence of long-term MR recurrence, because
patients were credited with the maximum time until the re-
turn of pathology (grade  3þMR). To better delineate the
exact timing of MR over time, serial echocardiograms and
statistical methods beyond the scope of the present study
should be used. Still, because we are generally more inter-
ested in the interval to clinical reintervention, instead of
the exact time at which grade  3þ MR has occurred, we
believe our methods were a rather reasonable proxy.
We our confident in our long-term mortality data; how-
ever, we acknowledge that the Social Security Death Index
was only reliable to November 1, 2011, at which point ac-
cess to this biomedical resource for vitality statistics was
terminated. With our end date for follow-up at December
31, 2011, it is plausible that a long-term mortality eventdiovascular Surgery c Volume 145, Number 5 1205
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(<5, given our mortality rate estimations by life analyses),
although it is our contention that if a few events were
missed, they were highly unlikely to have had a substantial
effect on our observations or conclusions. With our annual
clinic and questionnaire follow-up protocols, the likelihood
of having missed an event within this period was small (the
total number of deaths in 2011 was 1, and the year with the
greatest mortality had<2/mo) and unlikely to have any
effect on our overall analysis.
We are also confident in our long-term reintervention
follow-up data, which were exhaustively accrued from
many sources, as discussed in the ‘‘Methods’’ section. De-
spite our exhaustive efforts, it is always plausible within
the framework of observational data collection that a reinter-
vention occurred at another institution that was not ac-
counted for in our follow-up data.CONCLUSIONS
Mini-MVS is effective, with excellent late results. The du-
rability of mini-mitral repair compared favorably with that
after conventional full sternotomymethods at late follow-up.References
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